Before Invest
ELI LILLY & Co logo

ELI LILLY & Co

LLY
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 14 years
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Thousands		LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Revenue
$ 79,665
$ 65,179
$ 45,043
$ 34,124
Costs, expenses, and other:
                  
Cost of sales
13,225
11,052
8,418
7,082
Research and development
14,596
13,337
10,991
9,313
Marketing, selling, and administrative
12,236
11,094
8,594
7,403
Acquired in-process research and development
4,544
2,910
3,280
3,800
Acquired in-process research and development and development milestones (Note 3)
-
-
-
-
Asset impairment, restructuring, and other special charges
1,431
484
861
68
Other—net, (income) expense
(37)
(571)
(219)
97
Costs, expenses, and other
46,070
39,448
32,362
27,570
Income before income taxes
33,595
25,731
12,680
6,555
Income taxes
6,884
5,091
2,090
1,314
Net income from continuing operations
-
-
-
-
Net income from discontinued operations (Note 19)
-
-
-
-
Net income
$ 26,711
$ 20,640
$ 10,590
$ 5,240
Earnings per share - basic and diluted
-
-
-
-
Earnings per share:
                  
Earnings from continuing operations - basic (in usd per share)
-
-
-
-
Earnings from discontinued operations - basic (in usd per share)
-
-
-
-
Basic (in dollars per share)
29.85
23
11.76
5.82
Earnings from continuing operations - diluted (in usd per share)
-
-
-
-
Earnings from discontinued operations - diluted (in usd per share)
-
-
-
-
Diluted (in dollars per share)
$ 29.79
$ 22.95
$ 11.71
$ 5.8
Shares used in calculation of earnings per share:
                  
Basic (in shares)
893,500
897,300
900,605
900,181
Diluted (in shares)
894,800
899,300
904,059
903,284